|
|
|
|
|
Sessions of Interest from the Upcoming American Society of Clinical Oncology Virtual Program
|
|
|
|
|
UroToday is excited to bring you audio discussions of ground breaking
data and written highlights by Medical Oncologists and Uro-oncologists, from the
ASCO 2020 Virtual Scientific Program, May 29-31 2020.
|
|
|
|
|
|
|
|
|
|
| Abstract 5569: CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide
|
|
|
|
|
|
|
|
| Abstract 5500: TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603)
|
|
|
|
|
|
|
|
| Abstract 5501: Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR)
|
|
|
|
|
|
|
|
| Abstract 5502: Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study
|
|
|
|
|
|
|
|
| Abstract 5602: HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer
|
|
|
|
|
|
|
|
| Abstract 5514: Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC)
|
|
|
|
|
|
|
|
| Abstract 5515: Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)
|
|
|
|
|
|
|
|
|
|
|
| Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis
|
|
|
|
|
|
|
|
| Abstract 5000: IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)
|
|
|
|
|
|
|
|
| Abstract 5011: Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study
|
|
|
|
|
|
|
|
| Abstract 5013: Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study
|
|
|
|
|
|
|
|
| Abstract 5020: Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO)
|
|
|
|
|
|
|
|
|
|
|
| Abstract 5001: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426
|
|
|
|
|
|
|
|
| Abstract 5002: SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC)
|
|
|
|
|
|
|
|
| Abstract 5005: Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE)
|
|
|
|
|
|
|
|
| Abstract 5009: Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC)
|
|
|
|
|
|
|
|
| Abstract 5010: Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade
|
|
|
|
|
|
|
|
|
|
Written Conference Summaries by Urologists and Medical Oncologists
|
|
|
|
|
|
|
|
|
|
Zach Klaassen, MD, MSc
|
| Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia. He attended medical school at St. George's University in Grenada, followed by clinical rotations and a research fellowship in the metro New York area. After completing his Urology residency in Augusta, he spent two years in Toronto as a Society of Urologic Oncology fellow, also obtaining a Masters of Science degree from the University of Toronto in Clinical Epidemiology.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hanan Goldberg, MD
|
| Assistant Professor, Urologic Oncology, SUNY Upstate Medical University, Syracuse, New York. Dr. Goldberg completed a three year fellowship in Uro-Oncology with the department of surgical oncology in the division of Urology at the Princess Margaret Hospital, University Health Network at the University of Toronto in Toronto, Canada.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jason Zhu, MD
|
| Jason Zhu, Fellow, Division of Hematology and Oncology, Duke University Medical Center, Durham, North Carolina. A physician at Levine Cancer Institute, Atrium Health, specializing in Medical Oncology and Internal Medicine.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alok Tewari, MD, Ph.D.
|
| A DFCI medical oncology fellow currently doing his post-doctoral research in genitourinary cancers. In the Brown lab he is interested in epigenetic mechanisms of resistance to various therapies in advanced GU malignancies. He received his undergraduate, medical and doctoral degrees from Duke University and moved up to Boston for internal medicine residency training. In his spare time he enjoys reading about non-science subjects and walking around outside.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christopher Wallis, MD, Ph.D.
|
| Christopher J.D. Wallis is a Urologic Oncology Fellow and Instructor in Urology at Vanderbilt University Medical Center. He obtained his Doctor of Medicine from the University of British Columbia, his Doctor of Philosophy in Clinical Epidemiology & Health Care Research from the Institute of Health Policy, Management & Evaluation at the University of Toronto, and completed his clinical residency in Urology at the University of Toronto affiliated hospitals.
|
|
|
|
|
|
|
|
|
|
|
